‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E Read more →

Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027 Read more →

Narcan maker Emergent BioSolutions eliminates top R&D role in sweeping restructuring Read more →